Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- PKD Program - Presentation of Data at ASN Conference
- S&P DJI Announces September 2026 Quarterly Rebalance
- PKD - Safety Committee Approves Dose Escalation
- ADOA Program Update
- PKD - Initiation of Multiple Dose Clinical Trial
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics